PROM1 and CTGF Expression in Childhood MLL-Rearrangement Acute Lymphoblastic Leukemia

Lu-Lu Wang1, Xue Tang1, Guichi Zhou1

  • 1Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.

Journal of Oncology
|October 24, 2022
PubMed

Insights

Infant acute lymphoblastic leukemia (ALL) with MLL-rearrangement (MLL-R) has a poor prognosis. This study identified PROM1 and CTGF as key genes linked to MLL-R ALL, suggesting they are potential therapeutic targets.

Area of Science:

  • Genomics
  • Molecular Biology
  • Pediatric Oncology

Background:

  • Infant acute lymphoblastic leukemia (ALL) with mixed-lineage leukemia gene (MLL) fusion has a poor prognosis.
  • Identifying genes coexpressed with MLL-rearrangement (MLL-R) is crucial for understanding and treating childhood ALL.

Purpose of the Study:

  • To identify critical coexpressed genes associated with MLL-rearrangement in childhood ALL.
  • To evaluate the prognostic significance of identified key genes in MLL-R ALL.

Main Methods:

  • Bioinformatic analysis integrating Oncomine, STRING, and Cytoscape databases.
  • Differential gene expression analysis of MLL-R ALL versus normal and MLL-germline ALL samples.
  • Survival analysis using Kaplan-Meier method on patient datasets (GSE68720, GSE19475, TARGET ALL).

Main Results:

  • Identified 35 functional genes in MLL-R ALL networks, highlighting PROM1, FLT3, CTGF, LGALS1, IGFBP7, ZNRF1, and RUNX2 as key genes.
  • Confirmed robust expression of these 7 key genes in MLL-R ALL compared to MLL-germline (MLL-G) ALL across multiple datasets.
  • High expression of PROM1 and CTGF correlated with significantly poorer overall survival in childhood ALL patients.

Conclusions:

  • PROM1 and CTGF are significantly upregulated in childhood MLL-R ALL.
  • PROM1 and CTGF represent promising therapeutic targets for improving outcomes in childhood MLL-R ALL.